IMPEDIMED LIMITED — Share Issue/Capital Change 2022

Oct 5, 2022

==> picture [226 x 43] intentionally omitted <==

ASX ANNOUNCEMENT

06 October 2022

Notification under section 708A(5)(e) of the Corporations Act 2001 (Cth)

ImpediMed Limited (ASX: IPD) ( ImpediMed, Company ) gives this notice in accordance with section 708A(5)(e) of the Corporations Act 2001 (Cth) ( Corporations Act ).

ImpediMed has issued 2,2782,077 new fully paid ordinary shares to executives and nonexecutive directors.

ImpediMed advises that:

1. The shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act and without a Product Disclosure Statement for the shares being prepared;

2. This notice is being given under section 708A(5)(e) of the Corporations Act;

3. As a disclosing entity, ImpediMed is subject to regular reporting and disclosure obligations;

4. As at the date of this notice, ImpediMed has complied with:

   • (i) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and

   • (ii) section 674 of the Corporations Act as it applies to the Company; and

5. As at the date of this notice, there is no excluded information of the type referred to in sections 708A(7) and 708A(8) of the Corporations Act that is required to be disclosed by the Company under 708A(6)(e) of the Corporations Act.

For and on behalf of the Board.

Leanne Ralph Company Secretary

Authorised for release by the Board of Directors of ImpediMed Limited.

Contact Details

Investor relations Contact:

Mike Bassett, ImpediMed T: +61 407 431 432 E: mbassett@impedimed.com

About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical technology company that non-invasively measures, monitors and manages fluid status and tissue composition using bioimpedance spectroscopy (BIS).

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO[®] for multiple indications including heart failure, lymphoedema, and protein calorie malnutrition sold in select markets globally.

For more information, visit www.impedimed.com.